Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |
---|---|
First Received Date † | June 4, 2008 |
Last Updated Date | April 15, 2009 |
Start Date † | June 2008 |
Current Primary Outcome Measures † |
|
Original Primary Outcome Measures † | Same as current |
Change History | Complete list of historical versions of study NCT00691964 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures † |
Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 12 [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ] |
Original Secondary Outcome Measures † | Same as current |
Descriptive Information | |
Brief Title † | Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
Official Title † | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
Brief Summary | Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis |
Detailed Description | |
Study Phase | Phase III |
Study Type † | Interventional |
Study Design † | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study |
Condition † | Plaque Psoriasis |
Intervention † |
|
Study Arms / Comparison Groups | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|
Recruitment Information | |
Recruitment Status † | Completed |
Enrollment † | 347 |
Completion Date | |
Primary Completion Date | March 2009 (final data collection date for primary outcome measure) |
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
Gender | Both |
Ages | 18 Years and older |
Accepts Healthy Volunteers | No |
Contacts †† | |
Location Countries † | United States |
Expanded Access Status | |
Administrative Information | |
NCT ID † | NCT00691964 |
Responsible Party | Nicky Mayber, Abbott |
Secondary IDs †† | |
Study Sponsor † | Abbott |
Collaborators †† | Paragon Biomedical |
Investigators † | |
Information Provided By | Abbott |
Verification Date | April 2009 |
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |